Tailoring Chemotherapy Decisions – TAILORx Study Results

4 June 2018 The American Society of Clinical Oncology (ASCO) annual meeting, a gathering of over 40,000 oncology specialists, was held this past weekend in Chicago. One of the studies that received a significant amount of press attention was the TAILORx study. There are several genomic tests which evaluate a tumor’s DNA to better determine how aggressive that tumor is,…

Read more

Does Breast Cancer Surgery Cause Metastatic Disease?

15 April 2018 Press coverage of a study recently published in the journal Science Translational Medicine has raised a lot of eyebrows and may be causing unnecessary worry in patients. The headline in USA Today noted “Healing process after breast cancer surgery may trigger cancer to spread, study says.” Not mentioned in the headline: the study was performed in mice.…

Read more

Direct to Consumer Genetic Testing

8 March 2018 The US Food and Drug Administration (FDA) has just approved an at-home test for certain DNA abnormalities known to be associated with an increased risk of breast and ovarian cancer. This is the first approval for a direct-to-consumer (DTC) breast cancer genetic test. Approximately 15% of patients diagnosed with breast cancer will be found to carry a…

Read more

Updated Breast Cancer Staging System – AJCC 8th Edition

1 January 2018 The American Joint Committee on Cancer (AJCC) has recently updated the staging system used for breast cancer. Cancer stage refers to the amount of cancer (size of the main tumor, spread to lymph nodes or other areas). The definitions of each stage vary depending on cancer type. Cancer stage often correlates with outcomes, and treatment recommendations usually…

Read more

Hormonal Contraceptives and Breast Cancer Risk

10 December 2017 A study published in the New England Journal of Medicine has shown that birth control pills and other forms of hormone based contraception (such as some intrauterine devices (IUDs) are associated with an increased risk of breast cancer. We’ve thought that the pills currently in use, which have much lower doses of estrogen and progesterone compared to…

Read more

Questions about Gadolinium Safety – MRI Contrast Dye

18 September 2017 Breast MRIs are used in some newly diagnosed breast cancer patients, especially those with dense breast tissue. In addition, they are used as a supplement to mammography in women who are found to be at high risk. In order to distinguish between normal and cancerous tissue, an intravenous contrast dye is used. For MRI studies, the contrast…

Read more

Genetic Testing in Women with a History of Breast or Ovarian Cancer

18 August 2017 Approximately 15%  of women diagnosed with breast cancer will be found to carry a mutation in one or more genes that predisposes to the cancer. The most familiar are the BRCA 1 and BRCA 2 genes. These are tumor suppressor genes, if mutated, they do not function properly and can result in a higher likelihood of cancer…

Read more

Active Surveillance for DCIS

20 March 2017 Over 50,000 women in the US are diagnosed every year with ductal carcinoma in-situ (DCIS), also known as Stage 0 breast cancer. DCIS is most often diagnosed on screening mammography and usually presents as a cluster of calcium deposits rather than a lump. In cases of DCIS, malignant appearing cells grow within the milk duct, but do not invade…

Read more

Genetic Testing for Breast Cancer

7 February 2017 A research letter recently published in the Journal of the American Medical Association found that patients diagnosed with breast cancer were not appropriately referred for genetic counseling and testing. The researchers used the SEER Registry to study the records of patients diagnosed between July 2013 – September 2014. Registry patients in the state of Georgia and Los…

Read more

Extended Endocrine Therapy – Not So Fast?

26 December 2016 Approximately 75% of breast cancers express the estrogen receptor – we term these breast cancers ER positive (ER+) or hormone-sensitive. Endocrine therapy refers to using medications to exploit this cancer cell property. Tamoxifen is used in premenopausal women and it blocks the estrogen receptor. In post-menopausal women, aromatase inhibitors (AI) are used which prevent estrogen from being produced…

Read more
Pages